Leiner OTC Sales Buoy Company Performance As Supplement Market Slows
This article was originally published in The Tan Sheet
Leiner Health Products is committed to reinvigorating its struggling dietary supplement business despite the sluggish market atmosphere and the recent success of the company's growing OTC portfolio.
You may also be interested in...
Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.
Leiner Health Products' private label OTC drug sales rose 51% to $98.8 mil. in fiscal 2000, boosted by a $33 mil. net sales contribution from the Granutec and Stanley businesses.
August launch planned for private label OTCs made by Leiner Health Products and priced at 20%-25% below brand name equivalents. Products include aspirin, acetaminophen, ibuprofen, naproxen sodium, cold & allergy tablets and complete allergy minitabs and capsules (Warner-Lambert's Benadryl), decongestant/antihistamine elixir and DM cough & cold elixir (Whitehall-Robins' Dimetapp), day/night cold & allergy liquid caplets (SmithKline Beecham's Contac Day/Night Cold & Flu), as well as antacids and laxatives. The e-tailer already stocks a line of private label supplements (1"The Tan Sheet" April 24, p. 14). Private label OTCs have contributed significantly to Leiner's growth (2see story, p. 14)